Swedish Orphan Biovitrum AB (DE:B6E)

FRANKFURT:B6E

B6E

Swedish Orphan Biovitrum AB

RESEARCH TOOLSreports

Want to see DE:B6E full AI Analyst Report?

Swedish Orphan Biovitrum AB (B6E) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

B6E Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Swedish

Orphan Biovitrum AB

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

B6E Stock 12 Month Forecast

Average Price Target

€43.27

▲(20.01% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Swedish Orphan Biovitrum AB in the last 3 months. The average price target is €43.27 with a high forecast of €49.01 and a low forecast of €32.36. The average price target represents a 20.01% change from the last price of €36.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"€22","29":"€29","36":"€36","43":"€43","50":"€50"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49.007509999999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€49.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.274556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€43.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.36345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.36</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,29,36,43,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.92,39.69596230769231,40.471924615384616,41.247886923076926,42.02384923076923,42.79981153846154,43.575773846153844,44.351736153846154,45.12769846153846,45.90366076923077,46.67962307692307,47.45558538461538,48.231547692307686,{"y":49.007509999999996,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.92,39.254965846153844,39.589931692307694,39.924897538461536,40.259863384615386,40.59482923076923,40.92979507692308,41.26476092307692,41.59972676923077,41.93469261538461,42.26965846153846,42.604624307692305,42.939590153846154,{"y":43.274556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.92,38.41565,37.911300000000004,37.40695,36.9026,36.398250000000004,35.8939,35.38955,34.8852,34.38085,33.8765,33.372150000000005,32.8678,{"y":32.36345,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€49.01

Average Price Target€43.27

Lowest Price Target€32.36

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

€49.01

Buy

35.91%

Upside

Initiated

05/06/26

Swedish Orphan Biovitrum initiated with a Buy at H.C. WainwrightSwedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright

Jon Berggren

Kepler Capital

€32.36

Buy

-10.25%

Downside

Reiterated

04/29/26

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Harry Gillis

Berenberg Bank

€46.23→€47.62

Buy

32.06%

Upside

Reiterated

04/28/26

Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank

Shirley Chen

Barclays

€36.52→€43.46

Buy

20.52%

Upside

Reiterated

02/24/26

Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at BarclaysSwedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays

Kirsty Ross Stewart

Exane BNP Paribas

€43.92

Buy

21.80%

Upside

Upgraded

02/10/26

Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas

Alistair Campbell

RBC Capital

€31.9→€32.36

Buy

-10.25%

Downside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Emmanuel Papadakis

Deutsche Bank

€26.35

Hold

-26.92%

Downside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

€49.01

Buy

35.91%

Upside

Initiated

05/06/26

Swedish Orphan Biovitrum initiated with a Buy at H.C. WainwrightSwedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright

Jon Berggren

Kepler Capital

€32.36

Buy

-10.25%

Downside

Reiterated

04/29/26

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Harry Gillis

Berenberg Bank

€46.23→€47.62

Buy

32.06%

Upside

Reiterated

04/28/26

Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank

Shirley Chen

Barclays

€36.52→€43.46

Buy

20.52%

Upside

Reiterated

02/24/26

Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at BarclaysSwedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays

Kirsty Ross Stewart

Exane BNP Paribas

€43.92

Buy

21.80%

Upside

Upgraded

02/10/26

Swedish Orphan upgraded to Outperform from Underperform at BNP ParibasSwedish Orphan upgraded to Outperform from Underperform at BNP Paribas

Alistair Campbell

RBC Capital

€31.9→€32.36

Buy

-10.25%

Downside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Emmanuel Papadakis

Deutsche Bank

€26.35

Hold

-26.92%

Downside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Swedish Orphan Biovitrum AB

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+6.62%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +6.62% per trade.

1 Year

Harry GillisBerenberg Bank

Success Rate

12/13 ratings generated profit

Average Return

+19.92%

Copying Harry Gillis's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +19.92% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+36.68%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.68% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

B6E Analyst Recommendation Trends

Rating

Jan 26

Feb 26

Mar 26

Apr 26

May 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, B6E has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. B6E average Analyst price target in the past 3 months is 43.27.

Each month's total comprises the sum of three months' worth of ratings.

B6E Financial Forecast

B6E Earnings Forecast

Next quarter’s earnings estimate for B6E is €0.30 with a range of €0.25 to €0.33. The previous quarter’s EPS was €0.35. B6E beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year B6E has Performed in-line its overall industry.

B6E Sales Forecast

Next quarter’s sales forecast for B6E is €667.94M with a range of €655.11M to €682.78M. The previous quarter’s sales results were €660.44M. B6E beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year B6E has Performed in-line its overall industry.

B6E Stock Forecast FAQ

What is DE:B6E’s average 12-month price target, according to analysts?

Based on analyst ratings, Swedish Orphan Biovitrum AB’s 12-month average price target is 43.27.

What is DE:B6E’s upside potential, based on the analysts’ average price target?

Swedish Orphan Biovitrum AB has 20.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Swedish Orphan Biovitrum AB a Buy, Sell or Hold?

Swedish Orphan Biovitrum AB has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Swedish Orphan Biovitrum AB’s share price target?

The average share price target for Swedish Orphan Biovitrum AB is 43.27. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €49.01 ,and the lowest forecast is €32.36. The average share price target represents 20.01% Increase from the current price of €36.06.

What do analysts say about Swedish Orphan Biovitrum AB?

Swedish Orphan Biovitrum AB’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Swedish Orphan Biovitrum AB?

To buy shares of DE:B6E, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Swedish Orphan Biovitrum AB (B6E) Stock Forecast & Price Target

B6E Analyst Ratings

B6E Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Swedish Orphan Biovitrum AB

B6E Analyst Recommendation Trends

B6E Financial Forecast

B6E Earnings Forecast

B6E Sales Forecast

B6E Stock Forecast FAQ

Detailed List of Analyst Forecasts